Zelluna / née Ultimovacs (ULTI) Fundamentale forhold

TekBot · januar 31, 2025, 6:02am

Ultimovacs ASA Reports Fourth Quarter 2024 Financial Results and Provides General Business Update

Oslo, January 31, 2025: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-
stage biotechnology company developing novel immunotherapies against cancer,
announces its fourth quarter 2024 results today.
…

Vis børsmeldingen

Conference call and webcast scheduled for January 31, 2025, at 09:00 (CET). Link
to webcast here
(https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20250131_3).

Fourth Quarter 2024 Business Update

Highlights

On December 17, 2024, Ultimovacs announced an agreement to combine its
business with Zelluna Immunotherapy AS and the intention to launch a fully
committed private placement. Zelluna Immunotherapy is a privately held
company pioneering the development of “off the shelf” T- Cell Receptor
Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers.
As part of the Business Combination, the Company will acquire 100% of the
shares in Zelluna, and issue 147,991,521 shares to the existing shareholders
of Zelluna. Furthermore, the fully committed Private Placement will comprise
of the issuance of 19,873,071 shares at a subscription price of NOK 2.60 per
share, raising gross proceeds of approx. MNOK 51.7.

The objectives of the combined company, Zelluna ASA, will be as follows:

a. Advance the world’s first MAGE-A4 targeting TCR-NK program, ZI-MA4-1,
into first-in-human clinical studies treating solid cancers
b. Develop the TCR-NK pipeline
c. Seek to unlock MultiClick technology potential
d. Wrap up the UV1 program

Financial update

Total operating expenses amounted to MNOK 121.0 in Q4 2024, and MNOK 223.7
in FY2024. MNOK 4.3 of the operating expenses was related to impairment of
UV1 patents, and MNOK 68.2 related to impairment of licenses and goodwill
covering the TET-technology, in total MNOK 72.5. Please see further
information below.

Total loss was MNOK 107.7 for the period and MNOK 201.1 in FY2024.

Net negative cash flow from operations was MNOK 24.7 in Q4 2024, and MNOK
163.4 in FY2024. Net decrease in cash and cash equivalents, not including
currency effects, was MNOK 23.4 during Q4 2024, and MNOK 157.1 in FY2024.
Cash and cash equivalents amounted to MNOK 107.4 as per December 31, 2024.

Write-down of asset values in Ultimovacs: As a reflection of the priorities
of the combined company and the implicit valuation of Ultimovacs in the
Business Combination, Ultimovacs has fully written down certain assets, with
a negative, non-cash P&L effect of MNOK 72.5.

The quarterly report and presentation will be published at 07:00 CET on January
31, 2025, and will be publicly available on the Ultimovacs website. The Company
will conduct a conference call and webcast at 09:00 CET the same day. Questions
can be submitted throughout the event. The webcast will be archived for replay
following the conference call. Link to webcast here
(https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20250131_3).

For further information, please see www.ultimovacs.com or contact:

Hans Vassgård Eid, CFO and Interim CEO, Ultimovacs ASA

Email: hans.eid@ultimovacs.com

Phone: +47 482 48632

About Ultimovacs
Ultimovacs is a clinical-stage biotechnology company developing novel
immunotherapies against cancer. The product candidate UV1 is an off-the-shelf
therapeutic cancer vaccine designed to enhance the benefits of immunotherapy and
improve cancer treatment efficacy for patients. UV1 triggers an immune response
against the shared cancer antigen telomerase, a target present in 85-90% of all
cancer indications across disease stages.

Ultimovacs is investigating the safety and efficacy of UV1 in a wide-ranging
clinical development program including various cancer indications and different
immunotherapy combinations. The ongoing Phase II program comprises five
randomized clinical trials in melanoma, mesothelioma, head and neck cancer,
ovarian cancer, and non-small cell lung cancer. More than 640 patients in the
U.S., Europe, and Australia are being enrolled in all Phase I and Phase II
trials in the current program.

Furthermore, Ultimovacs is developing a novel conjugation technology, initially
formed to support the expansion of our vaccine pipeline. With the objective of
driving value and future pipeline growth, this flexible conjugation technology
has the potential to be broadly applicable to a variety of therapeutic
modalities, such as innovative drug conjugates with favorable pharmacological
properties, and in multiple disease areas.

Ultimovacs and the shareholders of Zelluna Immunotherapy AS have entered into a
definitive business combination agreement to combine the two companies in a
share exchange transaction.

Ultimovacs is listed on the Euronext Oslo Stock Exchange (OSE:ULTI).

This information is subject of the disclosure requirements pursuant to Section
5-12 in the Norwegian Securities Trading Act.

This stock exchange announcement was published by Joachim Midttun, Financial
Manager at Ultimovacs ASA, on January 31, 2025 at 07:00 CET.

Kilde

TekBot · februar 13, 2025, 8:10am

Financial calendar

TekBot · februar 13, 2025, 4:31pm

Ultimovacs ASA: Cancellation of subsequent repair offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO
THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY JURISDICTION IN WHICH SUCH
RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.
…

Vis børsmeldingen

Oslo, 13 February, 2025: Reference is made to the stock exchange announcement
published by Ultimovacs ASA (“Ultimovacs” or the “Company”) on 17 December 2024
regarding the agreement to combine its business with Zelluna Immunotherapy AS,
the fully committed private placement (the “Private Placement”), and the
intention to carry out a subsequent repair offering (the “Subsequent Offering”),
depending, inter alia, on the development of the price of the shares in the
Company after completion of the Private Placement.

The board of directors of the Company has resolved not to proceed with the
Subsequent Offering.

The background for the cancellation is that the Company’s shares have traded at
or below the subscription price in the Private Placement for an extended period
of time and at sufficient volumes. Shareholders wishing to reduce the dilutive
effect of the Private Placement have thus had the opportunity to purchase shares
in the market at prices at or below the price which would have been the
subscription price in the Subsequent Offering.

For further information, please see www.ultimovacs.com
(https://www.ultimovacs.com) or contact:

Hans Vassgård Eid, CFO and Interim CEO, Ultimovacs ASA
Email: hans.eid@ultimovacs.com
Phone: +47 482 48632

Kilde

TekBot · februar 28, 2025, 1:47pm

Ultimovacs ASA: Approval and publication of prospectus

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO
THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY JURISDICTION IN WHICH SUCH
RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.
…

Vis børsmeldingen

Oslo, 28 February, 2025: Reference is made to the stock exchange announcement by
Ultimovacs ASA (“Ultimovacs” or the “Company”) on 17 December 2024 regarding the
agreement to combine its business with Zelluna Immunotherapy AS (the “Business
Combination”) and the fully committed private placement (the “Private
Placement”).

The Company has prepared a prospectus in connection with the listing on Euronext
Oslo Børs of (i) the 147,991,521 shares in the Company, each with a nominal
value of NOK 0.10, (the “Consideration Shares”) to be issued in connection with
the Business Combination and (ii) the 19,873,071 shares in the Company, each
with a nominal value of NOK 0.10, (the “Private Placement Shares”) to be issued
in the Private Placement.

The prospectus has today, 28 February 2025, been approved by the Financial
Supervisory Authority of Norway. The prospectus will be made available on
Presentations and publications - Ultimovacs prior to the
first day of trading in the Consideration Shares and Private Placement Shares
subject to the conditions set out below.

Subject to completion of the Business Combination, the first day of trading in
the Consideration Shares and the Private Placement Shares is expected on or
about 4 March 2025. No assurance can currently be given that the listing will
take place in time or at all.

For further information, please see www.ultimovacs.com
(https://www.ultimovacs.com) or contact:

Hans Vassgård Eid, CFO and Interim CEO, Ultimovacs ASA
Email: hans.eid@ultimovacs.com
Phone: +47 482 48632

Kilde

Boms · februar 28, 2025, 1:49pm

Det var ikke mange dagene, før det er endelig gjennomført en fusjon, og et nytt og forhåpentligvis lyst kapittel kan skrives.

TekBot · mars 3, 2025, 3:47pm

Zelluna ASA [ZLNA]: The first ever cell therapy company to list on the Oslo Stock Exchange following successful completion of the business combination and private placement

Oslo, Norway, 03 March, 2025 - Zelluna ASA, a company pioneering allogeneic ‘off
the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment
of cancer, today announces the successful completion of a Business Combination
…

Vis børsmeldingen

and Private Placement. All conditions for completion of the Business Combination
have been met, including, confirmation by Euronext Oslo Børs of the continued
listing, approval of the Prospectus and regulatory clearances.

The share capital increases relating to the issuance of the Consideration Shares
and the Private Placement Shares was registered today on 3 March 2025 with the
Norwegian Register of Business Enterprises. The new share capital of the Company
is now NOK 20,227,065.30 divided into 202,270,653 shares, each with a nominal
value of NOK 0.10. Consequently, the Business Combination has now been
completed.

The name change from Ultimovacs ASA to Zelluna ASA has also been registered with
the Norwegian Register of Business Enterprises. The name change and the first
day of trading is expected to be implemented on Euronext Oslo Børs on or about
4 March 2025. The ticker code of the Company will change from “ULTI” to “ZLNA”.

Cell therapies are a class of therapeutics that have delivered “cures” in late-
stage cancer patients with a number of therapies approved mainly for liquid
cancers and several with data from fewer than 100 patients for regulatory
approval. Despite successes two key challenges remain: 1) solid cancers -
representing the largest cancer burden worldwide (e.g. lung, ovarian, breast and
head & neck cancers) - remain tougher to treat, and 2) scaling and global access
to treatment is highly limited with current therapies.

Zelluna has built a platform to take the curative potential of cell therapies to
solid cancers at a global scale. Zelluna does this through a game changing and
highly differentiated “off the shelf” cell therapy platform, which merges
clinically validated components - TCR targeting with NK cells - to form TCR-NK.
This novel TCR-NK platform is protected by strong intellectual property opening
up the potential for an unprecedented opportunity to capture the market of an
entire therapeutic field. The lead asset nearing the clinic is a world’s first
MAGE-A4 targeting TCR-NK which can potentially be used to treat a range of solid
cancers with unmet medical need in high value cancer markets.

The Board of Directors and management team of Zelluna ASA include serial biotech
entrepreneurs with deep experience in discovery through to clinical development
of TCR, cell-based and immunotherapy products including marketed products. The
management team comprise the following:

Namir Hassan, CEO
Hans Vassgård Eid, CFO
Anders Holm, COO/Head of BD
Jens Bjørheim, CMO
Luise Weigand, Head of Research
Emilie Gauthy, Head of CMC
Øivind Foss, Head of Clinical Operations
Julia Ino, Head of Project Management

Namir Hassan, the Chief Executive Officer of Zelluna ASA, commented:
“Today marks a pivotal moment in Zelluna’s journey, as we are poised to enter
the public markets. Through the unwavering dedication of our team, board and
investors, we have pioneered the TCR-NK platform from basic research, to the
public markets with an exciting, worlds first MAGE-A4 lead program heading
towards the clinic. Listing on the Oslo Stock Exchange opens new doors for
growth and innovation, enhances our visibility and provides the financial
flexibility needed to accelerate the development of our groundbreaking cell
therapies getting them closer to solid cancer patients who need them.”

Anders Tuv, Chairman of the Board of Directors, commented:
“Zelluna’s listing on the Oslo Stock Exchange marks a defining step in our
evolution as a highly differentiated, globally positioned cell therapy company.
Our world leading position in the TCR-NK therapeutic field, and ambition to
drive cell therapy application in solid tumours on a global scale potentially
promises massive commercial opportunities. To realise this vision and maximize
both patient impact and shareholder value, we are backed by an internationally
recognized management team and life science specialist investors who share our
bold ambitions.”

Additional information regarding the transactions referred to above can be found
in the stock exchange announcements published on (i) 17 December 2024 regarding
the agreement to combine the businesses of Ultimovacs ASA (now Zelluna ASA) (the
“Company”) and Zelluna Immunotherapy AS (the “Business Combination”) and the
fully committed private placement (the “Private Placement” and together with the
Business Combination, the “Transactions”), (ii) 9 January 2025 regarding the
extraordinary general meeting, which, inter alia, resolved to issue 147,991,521
new shares connection with the Business Combination (the “Consideration Shares”)
and 19,873,071 shares in connection with the Private Placement (the “Private
Placement Shares”) and (iii) on 28 February 2025 by the Norwegian Financial
Supervisory Authority regarding the approval of a prospectus for listing of the
Consideration Shares and Private Placement Shares (the “Prospectus”).

For further information, please contact:
Namir Hassan, CEO, Zelluna ASA
Email: namir.hassan@zelluna.com
Phone: +44 7720 687608

Hans Vassgård Eid, CFO, Zelluna ASA
Email: hans.eid@zelluna.com
Phone: +47 482 48632

About Zelluna ASA
Zelluna’s mission is to deliver transformative treatments with the capacity to
cure advanced solid cancers, in a safe and cost-efficient manner, to patients on
a global scale. The Company aims to do this by combining the most powerful
elements of the immune system through pioneering the development of “off the
shelf” T cell receptor (TCR) guided natural killer (NK) cell therapies (TCR-NK).
The TCR-NK platform offers a unique mechanism of action with broad cancer
detection capability to overcome the diversity of tumours and will be used “off
the shelf” to overcome scaling limitations of current cell therapies. The lead
program is a world’s first MAGE-A4 targeting “off the shelf” TCR-NK for the
treatment of various solid cancers; a pipeline of earlier products follows. The
Company is led by a management team of biotech entrepreneurs with deep
experience in discovery through to clinical development of TCR and cell-based
therapies including marketed products.

Kilde

Has · mars 22, 2025, 1:05pm

DNBs Geir Hiller-Holom tegner her et spennende bilde av Zelluna. Kan være verd å lytte til.

Boms · april 1, 2025, 6:59am

@pdx Zelluna har vel ny ISIN nå så man trenger kanskje en ny link for å få børsmeldinger automatisk lastet inn?

Ellers så er det spleis av aksjer 10 : 1 i dag.

Her er mailen fra selskapet som kom kl 08:00 :

Zelluna ASA [ZLNA]: Ex reverse share split today

Oslo, Norway, 1 April 2025

Issuer name: Zelluna ASA

Ex. date: 1 April 2025

Type of corporate action: Reverse share split

Other information:

Reverse split ratio – ten (10) old shares give one (1) new share.

New par value of NOK 1 per share

New ISIN is NO 001 3524942.

For further information, please contact:

Hans Vassgård Eid, CFO, Zelluna ASA

Email: [hans.eid@zelluna.com]

Phone: +47 482 48632

TekBot · april 4, 2025, 1:22pm

Zelluna ASA [ZLNA]: Notification of transaction by close associate of primary insider

Oslo, Norway, 4 April, 2025 - Reference is made to the stock exchange notice
published by Zelluna ASA (the “Company”) on 27 March 2025 regarding key
information on the reverse share split at a ratio of 10:1.
…

Vis børsmeldingen

Radforsk Investeringsstiftelse (“Radforsk”) has previously agreed with the
Company to make available, without any compensation a, necessary number of
shares to ensure that all fractions of shares are rounded up to the nearest
whole share, thus avoiding that shareholders will have its shareholdings rounded
off downwards.

Radforsk has today transferred a total of 1730 shares to DNB Bank ASA,
registrar’s department, for deletion, to ensure that all fractions of shares are
rounded up to the nearest whole share in the reverse share split.

The Company has thus received the following notification of a transaction made
by a close associate of a primary insider:

Radforsk Investeringsstiftelse, a close associate of Anders Tuv, Chair of
the board of directors and primary insider of the Company, has today
transferred 1730 existing shares in the Company to DNB Bank ASA, registrar’s
department, at a price of NOK 1 per share (equal to the par value).

The notification concerning the above subscription is attached hereto.

For further information, please contact:

Hans Vassgård Eid, CFO, Zelluna ASA
Email: hans.eid@zelluna.com (mailto:[%20hans.eid@zelluna.com])
Phone: +47 482 48632

About Zelluna ASA
Zelluna’s mission is to deliver transformative treatments with the capacity to
cure advanced solid cancers, in a safe and cost-efficient manner, to patients on
a global scale. The Company aims to do this by combining the most powerful
elements of the immune system through pioneering the development of “off the
shelf” T cell receptor (TCR) guided natural killer (NK) cell therapies (TCR-NK).
The TCR-NK platform offers a unique mechanism of action with broad cancer
detection capability to overcome the diversity of tumours and will be used “off
the shelf” to overcome scaling limitations of current cell therapies. The lead
program is a world’s first MAGE-A4 targeting “off the shelf” TCR-NK for the
treatment of various solid cancers; a pipeline of earlier products follows. The
Company is led by a management team of biotech entrepreneurs with deep
experience in discovery through to clinical development of TCR and cell-based
therapies including marketed products.

Kilde

TekBot · april 8, 2025, 6:44am

Financial calendar

TekBot · april 22, 2025, 5:48am

Zelluna Reaches Major Milestone with Manufacturing Process Established in Preparation for Clinical Entry of ZI-MA4-1, its Novel TCR-NK Therapy Targeting Solid Tumours

Oslo, Norway, 22 April 2025 - Zelluna (OSE: ZLNA), a company pioneering
allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells
for the treatment of cancer, has successfully developed, scaled and automated
…

Vis børsmeldingen

its proprietary manufacturing process for its TCR-NK cell therapies. This
milestone represents a major advancement in the Company’s preparation for
clinical entry to provide life-changing, innovative treatments for patients
battling cancer. The proprietary manufacturing process is applicable to any
product emerging from the Company’s pipeline which means any TCR-NK product can
be plugged into the established manufacturing process strengthening Zelluna’s
dominance of the TCR-NK therapeutic field.

Establishing and locking down a manufacturing process marks an essential step
towards the production of TCR-NK cell therapies for clinical development and
future commercialization. Based on the established manufacturing process,
hundreds of doses could be produced from a single manufacturing batch
highlighting scalability and low cost of goods potential. Zelluna continues to
advance its lead TCR-NK cell therapy candidate ZI-MA4-1 in preparation for a
filing in the second half of 2025 to begin clinical development targeting a
variety of solid tumours.

Zelluna has partnered with Catalent, a leading global contract development and
manufacturing organization (CDMO), for process development and manufacturing.
Catalent brings significant experience in cell therapy manufacturing in
compliance with the highest quality standards.

Emilie Gauthy, Head of CMC at Zelluna, commented: “Today marks an important
milestone for Zelluna and a crucial step in the development of our novel off the
shelf TCR-NK therapies, giving us the potential to make them widely accessible
for patients. For any cell therapy, the complexities and challenges of
manufacturing are well known and so establishing an efficient process represents
a significant achievement. I am therefore incredibly proud of what our team
together with our CDMO partners have achieved in transforming a groundbreaking
concept from the laboratory into a tangible lead product ready for clinical
development that can potentially benefit a wide cross-section of cancer
patients.”

The established process has delivered its first TCR-NK cell therapy product in
the form of Zelluna’s lead asset ZI-MA4-1 targeted at solid tumours, with high
standards of purity, potency, and safety, designed to meet the needs of patients
while also adhering to the latest regulatory requirements. ZI-MA4-1 has shown
promising results in preclinical studies, demonstrating the potential of TCR-NK
cells to effectively target and eliminate diverse cancer types, in ways that can
overcome cancer escape, and with an anticipated favorable safety profile
compared to benchmarked cell-based immunotherapies. The company is now well-
positioned to move forward with clinical trials and bring this groundbreaking
therapy closer to patients.

“We are thrilled to have successfully locked down our TCR-NK cell therapy
manufacturing process,” said Namir Hassan, CEO of Zelluna. “This pivotal
achievement not only demonstrates our capability to produce high-quality,
scalable TCR-NK cell therapies, but also underscores our commitment to advancing
next-generation immunotherapies that could transform the treatment of solid
tumours and improve patient outcomes. This accomplishment is a testament to the
exceptional talent and relentless drive of our team and partners.”

For further information, please contact:

Namir Hassan, CEO, Zelluna ASA

Email: namir.hassan@zelluna.com (mailto:namir.hassan@zelluna.com)

Phone: +44 7720 687608

Hans Vassgård Eid, CFO, Zelluna ASA

Email: hans.eid@zelluna.com (mailto:[%20hans.eid@zelluna.com])

Phone: +47 482 48632

About Zelluna ASA

Zelluna’s mission is to deliver transformative treatments with the capacity to
cure advanced solid cancers, in a safe and cost-efficient manner, to patients on
a global scale. The Company aims to do this by combining the most powerful
elements of the immune system through pioneering the development of “off the
shelf” T cell receptor (TCR) guided natural killer (NK) cell therapies (TCR-NK).
The TCR-NK platform offers a unique mechanism of action with broad cancer
detection capability to overcome the diversity of tumours and will be used “off
the shelf” to overcome scaling limitations of current cell therapies. The lead
program is a world’s first MAGE-A4 targeting “off the shelf” TCR-NK for the
treatment of various solid cancers; a pipeline of earlier products follows. The
Company is led by a management team of biotech entrepreneurs with deep
experience in discovery through to clinical development of TCR and cell-based
therapies including marketed products.

For more information, please visit www.zelluna.com
(https://eur02.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.zelluna.co
m%2F&data=05%7C02%7Cnamir.hassan%40zelluna.com%7Ced8cddea86b14997fdfe08dd7dca316
c%7Ccede8a9004b24ee9b76f4516596ada0e%7C0%7C0%7C638805029541430284%7CUnknown%7CTW
FpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTW
FpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=9pTn8Iupu8%2FABSEmbfBxpII6MF1KmK%2BJj8
k3MozVlII%3D&reserved=0)

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to Section 5-12 in the Norwegian Securities Trading Act.

This stock exchange announcement was published by Hans Vassgård Eid, CFO of
Zelluna ASA, on 22 April 2025 at 07.45 CET.

Kilde

Has · april 22, 2025, 7:51am

Emisjonskursen for et par måneder siden var tilsvarende 26.

Med bar 10% av aksjene i omløp har tradere ved press halvert kursen.

Skal vi i første omgang like hurtig opp til emisjonskurs?

InVivo · april 22, 2025, 8:54am

Er risikovilligheten tilbake i Norsk biotek?

Ut fra denne meldingen kan det se sånn ut

Boms · april 22, 2025, 9:12am

Den er vel bare tilbake etter en stund med små salg på dårlige dager.

Men det er også en ikke uvesentlig nyhet for et produkt som er «first-in-class».

InVivo · april 22, 2025, 9:37am

Heftig mcap sammenlignet med feks Nykode og Oncoinvent. Vi snakker om et preklinisk biotek i Norge, så jeg vil si mcap er oppsiktsvekkende høy!

Enten er Zelluna overpriset eller de andre underpriset.

Boms · april 22, 2025, 9:47am

Tja, binære case som jo de fleste biotek selskap er vil jo alltid ende opp med ha vært ekstremt feilpriset. Lykkes Zelluna vil dagens aksjekurs se ut som en vits, mislykkes de er den 99 % for høy.

Litt mer spesifikt så tror jeg de har et stort potensiale om de får “medisinen sin” til å vise resultater, og de har antagelig en relativt sett kort vei til markedet. Fall-back strategien deres kan være å selge IP som de hevder har en en ganske unik patentbeskyttelse.

Link til ppt: https://www.zelluna.com/content/2024/12/20241218-Webcast-presentation-Ultimovacs-Zelluna-vF.pdf

InVivo · april 22, 2025, 9:57am

Dette er jo det klassiske argumentet for stort sett all biotek.

Og derfor skjønner jeg ikke hvorfor Zelluna prises så mye høyere enn annen norsk biotek, spesielt ikke når de ikke en gang har data fra mennesker.

Pk2k · april 22, 2025, 9:59am

Lav omsetning som styrer kursen mange % begge veier

BalleKlorin · april 22, 2025, 10:44am

Vanskelig å sammenligne dette med annen norsk biotek. Såvidt meg bekjent ingen andre norske selskaper som utvikler celleterapi og dette er noe helt annet enn vaksiner.

InVivo · april 22, 2025, 10:55am

Hørt den før